An interventional study of Chinese version of Making Choices Feeding Options for Patients with Dementia Decision Aid in Dementia Caregivers, End of Life Decision Making and Advanced Dementia, sponsored by Yaolin Pei. Recruiting at 1 site in United States. Open to participants aged 21 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Yaolin Pei · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 118 studies in Death with a site in United States — 13 open to participants now, 27 under way, 1 of them phase 3. Death · United States.
Among the 118 studies in Death with a site in United States, this one is the 60th largest by planned enrollment of the 79 interventional ones that give a count, is one of 5 that started in 2026, is one of 68 with no phase, reaches primary completion later than 15 of the 26 other live ones, and was the 115th registered.
457 studies on the registry are indexed under Death; 85 are open to participants now.
Browse Death studies →13 of the 118 studies in Death with a site in United States are open now. Recruiting first, the newest first:
University of Michigan · Sites in United States
Ages 18+
University of Illinois at Chicago · Sites in United States
Ages 18–80
Massachusetts General Hospital · Sites in United States
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+ · Healthy volunteers
University of South Florida · Sites in United States
Ages 21+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 58 Death studies recruiting now, 43 (74%) set no upper age limit and 8 (14%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 21 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
118 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 6 · Phase 4 1
First in 1980; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 160 across 211 interventional studies indexed under Death.
Median enrollment 154 across the 79 interventional studies, 272 across the 39 observational. Of the 78 that completed or were terminated, 17 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 118 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Yaolin Pei as lead sponsor.
Yaolin Pei has 1 study filed under Death — fewer than ten, so there is no comparison to draw.
7 of the studies in Death with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06293456Memorial Sloan Kettering Cancer CenterStudy of Poetic Dignity Therapy for Sexual and Gender Minority Patients With Cancer | 2027-01 |
| NCT04261088National Institutes of Health Clinical Center (CC)Assisted Suicide in Switzerland | 2027-01-31 |
| NCT05446272University of PennsylvaniaThe Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial | 2027-03-31 |
| NCT04515810Fred Hutchinson Cancer CenterMobile Health Application (PACT) to Improve Engagement in Advance Care Planning | 2027-05-31 |
| NCT07370311Yaolin PeiA Culturally Adapted Decision Aid Intervention to Support Chinese American Dementia Caregivers in Feeding-Related Decisions | 2027-07-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 118 studies in Death with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Family caregivers of people with dementia have to decide between tube feeding and hand feeding when persistent eating problems arise. This decision can be difficult for Chinese American dementia caregivers, due to the interplay of culture, potential absence of a patient's advance directive, poor understanding of dementia, and lack of knowledge on the risks and benefits of tube feeding. In this polit study, the principal investigator examines whether a culturally adapted decision aid intervention regarding feeding options named "Chinese version of Making Choices Feeding Options for Patients with Dementia Decision Aid" (CMCFODA) will improve Chinese American caregivers' decision-making about feeding options in patients with moderate or advanced dementia. The proposed study advances the field by providing critical evidence to inform the development and implementation of culturally adapted decision support interventions in end-of-life dementia care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1. Receive usual care (including information from healthcare providers) 2. Receive electrical version of decision aid after all of the data collection
1. Receive both the electronic and paper version of CMCFODA 2. Receive an individualized decision coaching within two weeks
Other: Chinese version of Making Choices Feeding Options for Patients with Dementia Decision Aid
Participants in the treatment group will receive the CMCFODA via zoom meeting or another secure video conferencing platform and an individualized decision coaching.
Decision conflict
SURE test for decisional conflict (0-4)
Time frame: Baseline; One-Month Follow-Up; Three-Month Follow-Up
Knowledge of feeding options and dementia
Questions to assess knowledge about feeding options and dementia
Time frame: Baseline; One-Month Follow-Up; Three-Month Follow-Up
Expectations of tube feeding
Questions about understanding differing expectations regarding feeding tube use
Time frame: Baseline; One-Month Follow-Up; Three-Month Follow-Up
Frequency of communication with other family members and healthcare providers
Questions to understand caregiver involvement, support, and information flow
Time frame: Baseline; One-Month Follow-Up; Three-Month Follow-Up
Preference of feeding option
Careful hand feeding, tube feeding, or unsure
Time frame: Baseline; One-Month Follow-Up; Three-Month Follow-Up
Preparation for decision-making scale (treatment group only)
Questions to assess the effect of the intervention by preparing for feeding option decision-making
Time frame: One-Month Follow-Up; Three-Month Follow-Up
The Feasibility of the CMCFODA study as measured by recruitment rates and the proportion of participants that decline participation.
The feasibility of the CMCFODA study will be measured by the proportion of eligible participants who decline to participate among those who were screened into the study.
Time frame: Enrollment
The Feasibility of the CMCFODA study as measured by participant retention, as indicated by the number of participants lost to follow-up.
Participant retention, as an aspect of feasibility, will be measured by the recorded number of participants number lost to follow-up.
Time frame: Enrollment, One-Month Follow-Up,Three-Month Follow-Up
Acceptability of the decision aid and decision coaching (only for the treatment group)
We will use developed questions to measure the acceptability of this intervention
Time frame: One Month Follow-Up
Plan to share: Yes — Data collected for the CMCFODA study will be shared only after the investigators have published findings addressing the study's specific aims. Intellectual property and data generated under this project will be managed in accordance with University of Texas at Austin and NIH policies, including the NIH Data Sharing Policy and Implementation Guidance. Following publication of the investigators' primary findings, access to the study databases and associated decision aid intervention tools will be made available for educational, research, and non-profit purposes.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code
Time frame: These data will be shared after the investigators have published the study's specific aims. Requests to access the code for this study will be reviewed by the investigative team and granted once feasibility, acceptability, and preliminary efficacy have been evaluated and the findings have been published.
Access criteria: Individuals who wish to access the data must agree to: (1) use the data solely for research purposes; (2) not attempt to identify any individual participant; (3) securely store the data using appropriate safeguards, such as password-protected servers and files; and (4) return and/or destroy the data upon completion of analyses.
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Jul 2027, 16 months after the start.
Of 107 non-industry interventional studies with no phase under Death, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 48. This study's planned 16 months is below that.
Counting every sponsor, half of 111 studies reached it within 23 months; a quarter within 13 and three quarters within 48.
Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2027 → Jul 2027, on Nov 4, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.